USRM (US Stem Cell) Debt-to-Asset : 131.57 (As of Dec. 2022)

View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Debt-to-Asset?

US Stem Cell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $8.27 Mil. US Stem Cell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.68 Mil. US Stem Cell's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2022 was $0.07 Mil. US Stem Cell's debt to asset for the quarter that ended in Dec. 2022 was 131.57.

US Stem Cell Debt-to-Asset Historical Data

The historical data trend for US Stem Cell's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Debt-to-Asset Chart

US Stem Cell Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

2.78

68.68

85.06

157.18

131.57

US Stem Cell Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Asset	Get a 7-Day Free Trial															157.18	59.21	120.58	50.90	131.57

Competitive Comparison of US Stem Cell's Debt-to-Asset

For the Biotechnology subindustry, US Stem Cell's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

US Stem Cell's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Debt-to-Asset falls into.

US Stem Cell Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

US Stem Cell's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(8.265	+	0.682)	/	0.068
	=	131.57

US Stem Cell's Debt-to-Asset for the quarter that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(8.265	+	0.682)	/	0.068
	=	131.57

US Stem Cell (OTCPK:USRM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

US Stem Cell Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

US Stem Cell Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323

Website

http://www.us-stemcell.com

US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

Executives

Murphy William P Jr	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson	director	14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman	director	5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart	director	19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson	director	1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella	officer: Chief Science Officer	1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee	director	54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth	director	1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich	officer: Vice President,Sales&Marketing	482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson	director	11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt	director, 10 percent owner, officer: Executive Chairman & CTO	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott	officer: VP of Public Relations	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas	director	13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325